Clinical Trials and Post-Market Side Effects

Clinical Education /

Multimedia /

Podcasts /

Browse Podcast Library

OCT 20, 2022

Clinical Trials and Post-Market Side Effects

By Jayanth S Sridhar, MD, Mohammed Ali Khan, MD, FACS, Ajay E Kuriyan, MD, Sarah Parker Read, MD, PHD

Experts InSight

33:50

Comprehensive Ophthalmology, Retina/Vitreous

Download Audio

Add to My Bookmarks

View

Mark Complete

Remove

Comments

Drs. Sarah Read, M. Ali Khan, and Ajay Kuriyan join a group discussion on incorporating newly approved medications into practice, focusing on real-world examples of Vuity (pilocarpine drops), brolucizumab, and drugs for dry AMD in trial.

Subscribe

Apple Podcasts

Spotify

Google Podcasts

RSS

Related

The History of Ophthalmology

Apr 18, 2024

Visual Snow

Apr 17, 2024

Episode 426: Journal Club Discussion Including Inflammation Events with Faricimab, DRCR Protocol AC Post Hoc Analysis, Outcomes of Surgery for PDR, AI Interpretation of Images

Apr 16, 2024

Episode 425: April 2024 Retinal Physician Preview Including Discussion of Pipeline Targets and Durability Based Agents for Wet Age Related Macular Degeneration and Diabetic Retinopathy

Apr 16, 2024

Artificial Intelligence–Assisted Eye Care

Apr 12, 2024
Most Commented

Loading, please wait...

There are no comments available.

Most Viewed

Loading, please wait...

Most Viewed content is not available.

All content on the Academy’s website is protected by copyright law and the Terms of Service. This content may not be reproduced, copied, or put into any artificial intelligence program, including large language and generative AI models, without permission from the Academy.

Clinical Trials and Post-Market Side Effects

OUR SITES

FOLLOW THE ACADEMY

Clinical Trials and Post-Market Side Effects

Related

OUR SITES

FOLLOW THE ACADEMY